Avid Bioservices and Taiwan Cell Manufacturing Company Highlight CGT Innovations at BIO 2025.
- Avid Bioservices operates a state-of-the-art facility, adhering to stringent GMP standards for cell and gene therapy manufacturing.
- The company provides comprehensive services, including IND-enabling CMC development and clinical production for various cell therapies.
- Avid Bioservices emphasizes collaboration to enhance cancer treatments and aims to showcase its capabilities at the 2025 BIO International Convention.
Taiwan Cell Manufacturing Company Showcases Cutting-Edge Capabilities in Cell and Gene Therapy
Taiwan Cell Manufacturing Company (tcmc), a leading Contract Development and Manufacturing Organization (CDMO) in the cell and gene therapy (CGT) sector, is set to highlight its advanced manufacturing capabilities at the upcoming 2025 BIO International Convention. Scheduled for June 16-19, this event gathers industry leaders and innovators to discuss breakthroughs in biopharmaceuticals. Headquartered in Hsinchu, Taiwan, tcmc is often referred to as the 'TSMC of the CGT industry' due to its renowned expertise in producing crucial components for immunotherapies, such as CAR-T cells and lentiviral vectors (LVV). The company operates a state-of-the-art commercial manufacturing facility that meets the stringent standards set by the Pharmaceutical Inspection Co-operation Scheme (PIC/S) Good Manufacturing Practices (GMP).
tcmc’s production capabilities extend beyond LVV manufacturing, encompassing the development of both genetically modified and non-genetically modified cell therapies. This includes CAR-T cells, dendritic cells (DC), cytokine-induced killer cells (CIK), natural killer cells (NK), and stem cells. In a landscape where innovative cancer treatments are critical, tcmc plays a vital role in providing comprehensive services that streamline the research and development process. Their offerings not only include IND-enabling Chemistry, Manufacturing, and Controls (CMC) development but also cover clinical production and commercial expansion, ensuring that clients can efficiently transition from early-stage research to market-ready products.
The company is dedicated to fostering partnerships with global innovators and healthcare professionals to enhance cancer treatment and health management. Through its integrated, end-to-end CDMO solution, tcmc aims to accelerate the development of CGT while optimizing costs for its clients. For example, their CAR-T therapy processes are designed to ensure a seamless experience, from initial research phases through clinical trials to commercial production. This commitment to innovation and excellence not only solidifies tcmc’s position as a key player in the global CGT landscape but also drives advancements in cell and gene therapies from Asia to the international market.
In addition to its manufacturing prowess, tcmc emphasizes the importance of collaboration in advancing cancer therapies. By working closely with industry leaders, the company seeks to address the evolving needs of the healthcare sector effectively. The upcoming BIO International Convention provides an ideal platform for tcmc to showcase its capabilities and engage with potential partners.
As the CGT industry continues to expand, tcmc’s focus on high-quality production and comprehensive services stands as a compelling advantage, positioning the company to meet the growing demand for innovative treatments.